<DOC>
	<DOCNO>NCT02403323</DOCNO>
	<brief_summary>This two-part , open-label extension safety monitoring study examine safety efficacy continue etrolizumab treatment patient moderate severely active Crohn 's disease previously enrol etrolizumab Phase III Study GA29144 .</brief_summary>
	<brief_title>Open-Label Extension Safety Study Patients With Crohn 's Disease Previously Enrolled Etrolizumab Phase III Study GA29144</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Part 1 Openlabel Extension : Patients previously enrol etrolizumab Phase III study GA29144 meet eligibility criterion openlabel etrolizumab describe protocol Part 2 Safety Monitoring : Patients participate etrolizumab Phase III study GA29144 eligible choose enter Part 1 Patients transfer Part 1 Completion 12week safety followup period prior enter Part 1 Openlabel Extension : Any new , significant , uncontrolled condition Part 2 Safety Monitoring : No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>